NCT07506369

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones. The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours: A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.

Conditions

• Obesity & Overweight

Interventions

Type	Name	Description
DRUG	Amylin (Pramlintide)	This a one of the pancreatic hormones investigated in this study. Pramlintide is used a surrogate for amylin due to the fibrillating properties of amylin
DRUG	Pancreatic Polypeptide (PP)	This a one of the pancreatic hormones investigated in this study.
DRUG	Placebo (NaCl 0.9 % solution)	This the placebo

Timeline

• Start date: 2026-04-01
• Primary completion: 2026-10-01
• Completion: 2028-10-01
• First posted: 2026-04-01
• Last updated: 2026-04-01

Locations

1 site across 1 country: Denmark